COMMUNIQUÉS West-GlobeNewswire

-
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
01/07/2025 -
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
01/07/2025 -
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
01/07/2025 -
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
01/07/2025 -
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
01/07/2025 -
The Real Jerry Maguire Meets Prof. Mike Chan of European Wellness Biomedical Group to Discuss Sports Injuries and Concussion Recovery
30/06/2025 -
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
30/06/2025 -
Human Appeal Announces First Summer UK Comedy Tour
30/06/2025 -
theranos Calls on President Trump to Pardon Suresh “Sunny” Balwani
30/06/2025 -
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
30/06/2025 -
Strongest Appetite Suppressant Over the Counter Now Available in USA - PhenQ Medically Accredited Craving Control Supplement OTC
30/06/2025 -
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
30/06/2025 -
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
30/06/2025 -
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
30/06/2025 -
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
30/06/2025 -
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
30/06/2025 -
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30/06/2025 -
PetVivo Reports Fiscal 2025 Results
30/06/2025 -
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/06/2025
Pages